2019年11月18日 · Preinfusion dim CD19 expression and rare CD19 – events in B-ALL do not affect relapses or responses to CD19-directed CAR T-cells. Prior blinatumomab treatment increases the rate of failure to achieve MRD – remission and CD19 – MRD and relapse.

2004年12月10日 · Our results indicated that a visible decrease in CD19 expression is observed in many B-cell lymphomas and is particularly common in follicular lymphomas, regardless of grade. An example of the usefulness of a gating strategy that uses CD19-dim lymphocytes to identify minimal residual disease is presented.

B-lymphocyte antigen CD19, also known as CD19 molecule (Cluster of Differentiation 19), B-Lymphocyte Surface Antigen B4, T-Cell Surface Antigen Leu-12 and CVID3 is a transmembrane protein that in humans is encoded by the gene CD19.

2019年11月26日 · Tisagenlecleucel, a chimeric antigen receptor (CAR) T-cell product targeting CD19 is approved for relapsed/refractory B-cell acute lymphoblastic leukemia (B-ALL). However, the impact of pretreatment variables, such as CD19 expression level, on leukemic blasts, the presence of CD19- subpopulations, a …

CD19 is classified as a type I transmembrane protein, with a single transmembrane domain, a cytoplasmic C-terminus, and extracellular N-terminus. CD19 is a biomarker for normal and neoplastic B cells, as well as follicular dendritic cells.

The CD19+CD56+ co-expressing cells (CD19+NK cells) are in green and both the FSC and SSC characteristics and CD19/CD56 dim pattern are shown. B - B cell associated antigens in CD19+NK cells identified by its CD19 dim expression (arrow), both specific (B1) and other associated B cell antigens (B2) are shown in a representative case.

Diminished expression of CD19 expression occurs frequently in B-cell lymphomas, in particular follicular lymphoma, and may be helpful in identifying B-cell lymphoma cells in complex cell mixtures such as bone marrow specimens.

The goal of this study was to determine the frequency of reduced (dim) CD20 expression relative to CD19 expression in DLBCL samples at diagnosis and to correlate this finding with clinical outcome in patients treated with CHOP with or without rituximab.

2013年4月18日 · Chimeric antigen receptor–modified T cells are capable of killing even aggressive, treatment-refractory acute leukemia cells in vivo. The emergence of tumor cells that no longer express the target...

CD19 is expressed by normal and neoplastic (=cancerous) B cells but is not expressed by T cells, monocytes, or granulocytes. CD19 protein appears early during B-cell maturation and is found during all stages of B-cell maturation, including plasma cells. CD19 is useful as an additional marker of B cell lineage in leukemias and lymphomas.